The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Myeloid Metaplasia

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Myeloid Metaplasia


High impact information on Myeloid Metaplasia


Chemical compound and disease context of Myeloid Metaplasia


Biological context of Myeloid Metaplasia


Anatomical context of Myeloid Metaplasia


Gene context of Myeloid Metaplasia


Analytical, diagnostic and therapeutic context of Myeloid Metaplasia


  1. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., Wiseman, G., Gray, L.A., Schroeder, G., Reeder, T., Zeldis, J.B., Tefferi, A. Blood (2003) [Pubmed]
  2. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B., Deininger, M.W. Blood (2005) [Pubmed]
  3. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. Marchetti, M., Barosi, G., Balestri, F., Viarengo, G., Gentili, S., Barulli, S., Demory, J.L., Ilariucci, F., Volpe, A., Bordessoule, D., Grossi, A., Le Bousse-Kerdiles, M.C., Caenazzo, A., Pecci, A., Falcone, A., Broccia, G., Bendotti, C., Bauduer, F., Buccisano, F., Dupriez, B. J. Clin. Oncol. (2004) [Pubmed]
  4. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Lee, J.W., Kim, Y.G., Soung, Y.H., Han, K.J., Kim, S.Y., Rhim, H.S., Min, W.S., Nam, S.W., Park, W.S., Lee, J.Y., Yoo, N.J., Lee, S.H. Oncogene (2006) [Pubmed]
  5. Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity. Gilbert, H.S., Ginsberg, H., Fagerstrom, R., Brown, W.V. Am. J. Med. (1981) [Pubmed]
  6. FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Carr, R.S., Peake, I.R., Reilly, J.T. Blood (2002) [Pubmed]
  7. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. Gilbert, H.S., Praloran, V., Stanley, E.R. Blood (1989) [Pubmed]
  8. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Jacobson, R.J., Salo, A., Fialkow, P.J. Blood (1978) [Pubmed]
  9. Effect of imatinib on haematopoietic recovery following idarubicin exposure. Ruchatz, H., Puttini, M., Cleris, L., Pilotti, S., Gambacorti-Passerini, C., Formelli, F. Leukemia (2003) [Pubmed]
  10. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Mesa, R.A., Tefferi, A., Gray, L.A., Reeder, T., Schroeder, G., Kaufmann, S.H. Leukemia (2003) [Pubmed]
  11. Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Wagner, H., McKeough, P.G., Desforges, J., Madoc-Jones, H. Cancer (1986) [Pubmed]
  12. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Besa, E.C., Nowell, P.C., Geller, N.L., Gardner, F.H. Cancer (1982) [Pubmed]
  13. Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. Colović, M.D., Wiernik, P.H., Janković, G.M., Vidović, A.D., Janosević, S., Basara, N.M. Eur. J. Haematol. (1999) [Pubmed]
  14. Portal hypertension secondary to myelofibrosis: a study of three cases. Alvarez-Larrán, A., Abraldes, J.G., Cervantes, F., Hernández-Guerra, M., Vizzutti, F., Miquel, R., Gilabert, R., Giusti, M., Garcia-Pagan, J.C., Bosch, J. Am. J. Gastroenterol. (2005) [Pubmed]
  15. Agnogenic myeloid metaplasia in an ovarian steroid cell tumor with virilization: a case report. Huang, C.W., Hsueh, S., Chang, M.Y. The Journal of reproductive medicine. (2004) [Pubmed]
  16. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. Massa, M., Rosti, V., Ramajoli, I., Campanelli, R., Pecci, A., Viarengo, G., Meli, V., Marchetti, M., Hoffman, R., Barosi, G. J. Clin. Oncol. (2005) [Pubmed]
  17. Impaired neutrophil function and myeloperoxidase deficiency in myeloid metaplasia. El-Maallem, H., Fletcher, J. Br. J. Haematol. (1977) [Pubmed]
  18. Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome. Delmer, A., Karmochkine, M., Cadiou, M., Gerhartz, H., Zittoun, R. Am. J. Hematol. (1990) [Pubmed]
  19. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. Wang, J.C., Novetsky, A., Chen, C., Novetsky, A.D. Br. J. Haematol. (2002) [Pubmed]
  20. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Tsimberidou, A.M., Thomas, D., O'Brien, S., Andreeff, M., Kurzrock, R., Keating, M., Albitar, M., Kantarjian, H., Giles, F. Cancer Chemother. Pharmacol. (2002) [Pubmed]
  21. Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Wang, J.C. Leuk. Lymphoma (2005) [Pubmed]
  22. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Wang, J.C., Chen, C., Lou, L.H., Mora, M. Leukemia (1997) [Pubmed]
  23. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Ho, C.L., Arora, B., Hoyer, J.D., Wellik, L.E., Mesa, R.A., Tefferi, A. Eur. J. Haematol. (2005) [Pubmed]
  24. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mesa, R.A., Elliott, M.A., Schroeder, G., Tefferi, A. Mayo Clin. Proc. (2004) [Pubmed]
  25. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Dingli, D., Schwager, S.M., Mesa, R.A., Li, C.Y., Tefferi, A. Cancer (2006) [Pubmed]
  26. Experience with splenectomy in auto-immune thrombocytopenia and agnogenic myeloid metaplasia. Heaton, A., Jacobs, P., Dent, D.M., Louw, J.H. S. Afr. Med. J. (1976) [Pubmed]
WikiGenes - Universities